H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) today and set a price target of $45.00. The company's shares closed last Friday at $6.85. According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.1% and a 29.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $30.19 average price target, which is a 338.2% upside from current levels.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-gets-a-buy-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Actinium Pharmaceuticals Charts.
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Actinium Pharmaceuticals Charts.